Background: Anaphylaxis during anaesthesia is a serious complication for patients and anaesthetists. Methods: The 6th National Audit Project (NAP6) on perioperative anaphylaxis collected and reviewed 266 reports of Grades 3e5 anaphylaxis over 1 yr from all NHS hospitals in the UK. Results: The estimated incidence was z1:10 000 anaesthetics. Case exclusion because of reporting delays or incomplete data means true incidence might be z70% higher. The distribution of 199 identified culprit agents included antibiotics (94), neuromuscular blocking agents (65), chlorhexidine (18), and Patent Blue dye (9). Teicoplanin comprised 12% of antibiotic exposures, but caused 38% of antibiotic-induced anaphylaxis. Eighteen patients reacted to an antibiotic test dose. Succinylcholine-induced anaphylaxis, mainly presenting with bronchospasm, was two-fold more likely than other neuromuscular blocking agents. Atracurium-induced anaphylaxis mainly presented with hypotension. Non-depolarising neuromuscular blocking agents had similar incidences to each other. There were no reports of local anaesthetic or latexinduced anaphylaxis. The commonest presenting features were hypotension (46%), bronchospasm (18%), tachycardia (9.8%), oxygen desaturation (4.7%), bradycardia (3%), and reduced/absent capnography trace (2.3%). All patients were hypotensive during the episode. Onset was rapid for neuromuscular blocking agents and antibiotics, but delayed with chlorhexidine and Patent Blue dye. There were 10 deaths and 40 cardiac arrests. Pulseless electrical activity was the usual type of cardiac arrest, often with bradycardia. Poor outcomes were associated with increased ASA, obesity, beta blocker, and angiotensin-converting enzyme inhibitor medication. Seventy per cent of cases were reported to the hospital incident reporting system, and only 24% to Medicines and Healthcare products Regulatory Agency via the Yellow Card Scheme. Conclusions: The overall incidence of perioperative anaphylaxis was estimated to be 1 in 10 000 anaesthetics.
anaphylactic reactions are allergic. Severity is commonly graded 1e5, although multiple grading systems exist. Mild reactions, Grades 1 and 2, do not constitute anaphylaxis. The 6th National Audit Project (NAP6) investigated Grades 3e5 reactions occurring in the perioperative period. Estimates of the incidence of perioperative anaphylaxis vary between 1:6000 to 1:20 000 anaesthetics. 2 In a large French study, the estimated incidence of immunoglobulin E (IgE)-mediated perioperative hypersensitivity (Grades 1e4) was 1:10 000 anaesthetics. 3 A UK questionnaire study of 4595 general anaesthetics estimated the incidence at 1:2297. 4 Perioperative anaphylaxis can vary over time and between different patient populations. Most studies have identified neuromuscular blocking agents (NMBAs) as the commonest culprit agents. In a French study, latex was the second commonest cause of anaphylaxis, unlike in a more recent UK study. 5 The majority of previous reports have included all grades of perioperative hypersensitivity, and all report similar patterns of clinical features. In a small number of cases, there can be single organ-system involvement, 35 and cutaneous features predominate in mild, noneIgE-mediated perioperative hypersensitivity. 35 The clinical features of severe anaphylaxis are very similar regardless of whether allergic or non-allergic. It is important to understand how severe anaphylaxis presents, as there is a wide differential diagnosis; no bedside testing; and a prompt, specific treatment is essential.
6e8
There are few large prospective studies of perioperative anaphylaxis with most looking retrospectively at cases that have been referred to allergy clinics for investigation. In addition, few studies have focused solely on severe (Grades 3e5) perioperative anaphylaxis or investigated relationships between presenting features and co-morbidities or concomitant medication. Individual trigger agents can elicit disparate patterns of presentation, including onset time, cardiovascular or respiratory system preponderance and outcomes can also differ: for example, the onset of anaphylaxis to chlorhexidine, latex, and Patent Blue dye can be delayed.
7,9e11

Methods
Methods are discussed in detail in an accompanying paper, but are described here briefly for clarity. 12 Denominator data included all cases under the care of an anaesthetist and were derived from the NAP6 Activity Survey 13 and NAP6 Allergen Survey. 14 Cases were reported using a two-part form: Part A reported soon after the anaphylactic event and Part B after the allergy clinic letter had been received by the anaesthetist. We defined allergic anaphylaxis by the presence of onset within 60 min, evidence of mast-cell mediator release (mast-cell tryptase), evidence of positive specific IgE (blood or skin tests), and exclusion of differential diagnoses. Four positive criteria were necessary for 'high' certainty and three for 'intermediate' certainty, but evidence of positive specific IgE (blood or skin tests) was essential for both levels of certainty. Non-allergic anaphylaxis was defined by the absence of positive specific IgE (blood or skin tests), but required onset within 60 min, evidence of mast-cell mediator release (mast-cell tryptase), and exclusion of differential diagnoses; four criteria for 'high' certainty; and three criteria for 'intermediate' certainty. Further information on the criteria for mast-cell tryptase positivity is given in the accompanying Methods paper. 12 Trigger agents were identified based on clinical history and allergy clinic investigations. The degree of certainty of attribution was achieved using rules described in the Methods paper, and was categorised as 'definite', 'probable', 'possible', or 'do not count'; only the first two categories were considered confirmed triggers.
Results
Of 541 cases reported, 412 included both Part A and Part B, or were fatalities (10) . One hundred and forty-six cases were excluded as a result of lack of detail or not meeting the criteria (93), being uninterpretable (27) , being judged not anaphylaxis (15) , or Grade 2 (9), and two were from non-NHS hospitals. 12 We identified 266 cases of Grades 3e5 anaphylaxis meeting our inclusion criteria. The Activity Survey 13 estimated that 3 126 067 anaesthetics were delivered in the UK in 2016, giving a calculated incidence of perioperative anaphylaxis of 1:11 752 [95% confidence interval (CI): 10 422e13 303].
Of 199 culprit agents (in 192 cases), 148 were identified as 'definite' and 51 as 'probable' (including seven cases where two probable culprits were identified). In 15 cases, the culprit was designated 'possible', and in 57 cases, the culprit could not be identified. The most common causes of perioperative anaphylaxis were antibiotics, followed by neuromuscular blocking agents, chlorhexidine, and Patent Blue dye (Table 1) . Most (58%) anaphylactic events occurred in the operating theatre, and 3% were before the induction of anaesthesia, 81% after the induction and before surgery, 13% during surgery, and 3% after surgery.
The incidences of the four most prevalent groups of drugs or agents were: 
Clinical features
The first clinical features were hypotension (46%), bronchospasm/high airway pressure (18%), tachycardia (9.8%), cyanosis/ oxygen desaturation (4.7%), bradycardia (3%), and reduced or absent capnography trace (2.3%) (Fig. 1) . Three patients presented with cardiac arrest (1.2%). Bronchospasm was the presenting feature more frequently in morbidly obese compared with other patients (Fig. 2 ) and in (mainly well-controlled) asthmatic patients (34%) compared with non-asthmatic patients (15%). Presentation was similar regardless of whether the mechanism was allergic or non-allergic. In approximately 1 in 20 cases, an awake patient reporting feeling unwell was the harbinger of anaphylaxis (Fig. 1) . Fifteen (5.6%) patients presented with isolated cardiovascular features and four (1.5%) with isolated respiratory features.
Hypotension as the presenting feature was proportionately more common in men than in women, perhaps related to coronary artery disease (24% vs 8.4%), beta blockers (27% vs 11%), and angiotensin-converting enzyme (ACE) inhibitor medication (21.2% vs 15.2%). Bronchospasm was more common in women: more women had asthma (25% vs 16%) ( Supplementary Fig. S1 ). There was a marked difference between NMBAs: bronchospasm was the most common presentation when succinylcholine (suxamethonium) was the trigger and hypotension with atracurium (Fig. 3) .
Considering the clinical features present at any time during the anaphylactic episode, hypotension was universal. Rash, seldom a presenting feature, developed in 56% of cases; bronchospasm/high airway pressure in 48%; tachycardia in 46%; cyanosis/oxygen desaturation in 41%; and a reduced/absent capnography trace in 33%. Bronchospasm at any time was also seen in a higher proportion of patients with asthma (59%) than others (46%). Again, this clinical pattern was very similar in the subgroup of allergic anaphylaxis patients (Fig. 4) .
Two notable features were almost absent. Rash was an uncommon presenting feature and was notably rare at any time in the most serious of cases. Airway problems were also rarely seen. A single patient required a front-of-neck airway to manage laryngeal oedema, but there were no other presentations or significant clinical features of airway difficulty.
Considering all cases, the onset time was <5 min in 66%, <10 min in 83%, <15 min in 88%, and <30 min in 95%. The onset times for individual agents are discussed below.
Fatalities, cardiac arrests, and profound hypotension
Ten patients died directly (eight) or indirectly (two) as a result of anaphylaxis, equating to an incidence of perioperative death from anaphylaxis of 1 in 313 000 and a per-case mortality rate of 1 in 26.6 cases. All fatalities were aged >46 yr, and half aged >66 yr. Two were ASA 2, six were ASA 3, and two were ASA 4. In the Activity Survey, 13 25% of patients were aged >66 yr, 77% were ASA 1e2, and <2% were ASA 4e5. Only one patient was of normal weight; four were overweight, one was obese, and four were morbidly obese. In the Activity Survey, 13 21% of all patients were obese or morbidly obese. None of the patients who died had a history of atopy or asthma. Five had coronary artery disease, most of whom were undergoing non-cardiac surgery; six were taking beta blockers and six were taking ACE inhibitors. Three were taking both and one patient was taking neither drug. Amongst the 266 reports of life-threatening anaphylaxis, 15% had evidence of coronary artery disease, 17% were taking beta blockers, and 17% were taking ACE inhibitors. Three of 10 patients were undergoing cardiac surgery. The surgical procedure was abandoned in nine cases and proceeded in one. Cardiac arrest occurred during the event in nine of 10 patients who died, and was pulseless electrical activity (PEA) in all fatal cases; none preceded by significant arrhythmias, although there was bradycardia in two. Management of these cases is described in the accompanying paper. 15 Forty (15%) patients, all of whom were adults, experienced cardiac arrest and 31 (78%) survived (Table 2 ). Most (81%) events occurred after the induction of anaesthesia and before surgery. A consultant was involved in all resuscitations. No particular trigger agents were associated with a higher risk of cardiac arrest. However, the survivors of cardiac arrest were younger, fitter, and had fewer co-morbid conditions than patients who died ( Table 3 ).
The presenting features are shown in Fig. 5 . Hypotension and bronchospasm/raised airway pressure were prominent, and rash was notably uncommon. Reduced or absent capnogram trace was not recorded as a presenting feature in any cases. Bradycardia was more common than tachycardia. Cardiovascular presenting features occurred in 25, respiratory in 11, and others in four. Of all cardiac arrests, 34 were PEA, four ventricular fibrillation/pulseless ventricular tachycardia, and two were asystole. Only six patients developed an arrhythmia before cardiac arrest: four bradycardia and two ventricular tachycardia. There were no reports of atrial fibrillation or supraventricular tachycardia. In adult patients, the lowest systolic BP recorded in the first hour after the event was 'unrecordable' in 56 (21%) cases, <50 mm Hg in 58 (22%) cases, and 51e59 mm Hg in 53 (20%) cases.
Antibiotics
Ninety-two cases of antibiotic-induced anaphylaxis were identified (including 94 definite or probable antibiotic culprits); 48% of all cases with identified culprits. The majority were caused by co-amoxiclav or teicoplanin, between them accounting for 89% of identified antibiotic culprits. The overall incidence of reported antibiotic-induced anaphylaxis was 4.0 per 100 000 exposures. The highest incidence was seen with teicoplanin (16.4 per 100 000 exposures) then co-amoxiclav (8.7 per 100 000 exposures). The relative anaphylaxis rate using cefuroxime as an index was 17.4 for teicoplanin and 9.2 for coamoxiclav (Table 4) . Of the 10 deaths, four were judged to be caused by an antibiotic. The incidences of the three most prevalent antibiotics were: in >150 000).
The onset of anaphylaxis was within 5 min in 74% of cases, 18% between 6 and 10 min, 5% between 11 and 15 min, and 2% between 16 and 30 min. None were delayed >30 min.
Of the 36 patients who reacted to teicoplanin, 20 (56%) stated before operation that they were allergic to penicillin. Of the 36 reactions, 16 were Grade 3, 18 were Grade 4, and 2 were Grade 5. Ten developed moderate and two severe harm (death). Amongst the 20 who likely received teicoplanin because of a history of allergy, two reactions were Grade 4 and one was Grade 5; six developed moderate harm and one died.
The NAP6 Allergen Survey 14 demonstrated the choice of antibiotic was influenced by preoperative allergy history in a quarter of patients who received teicoplanin or vancomycin. In <1% of cases, communication failure led to an antibiotic being administered despite a relevant positive allergy history. Two cases were judged preventable by better allergy history communication.
There were 18 antibiotic-related reactions related to test doses: in 10 (53%) cases, the patient reacted to the test dose itself, which ranged from 5% to 30% of the therapeutic dose, and the other eight patients reacted to the full dose, which was given within 1 min of the test dose in all but one case (given within 10 min). There was no evidence that administration of a 'test dose' of antibiotic reduced the severity of an ensuing 
Neuromuscular blocking agents and reversal agents
Triggers were identified as neuromuscular blocking agents in 64 cases, 25% of all cases, including 32% of cases leading to cardiac arrest or death. Ninety-five per cent of NMBA-induced reactions presented within 5 min. The culprit neuromuscular blocking agents were rocuronium (42% of cases), atracurium (35%), succinylcholine (22%), and mivacurium (1.5%). There were no cases of anaphylaxis caused by vecuronium, pancuronium, or cisatracurium, although these only accounted for 4.4% of all neuromuscular blocking agent use. 14 The review panel identified non-allergic anaphylaxis to atracurium in three cases, and to mivacurium in a single case. The incidence per 100 000 exposures is a more meaningful metric than the occurrence rate. The overall incidence of reported neuromuscular blocking agent-induced anaphylaxis was 5.3 per 100 000 exposures. The highest incidence was seen with succinylcholine (11.1 per 100 000 exposures), while all others were similar to each other. Succinylcholine was twice as likely to cause anaphylaxis than any other neuromuscular blocking agent ( Table 5 ).
The incidences of the three most prevalent neuromuscular blocking agents was: In 71% of cases where the anaesthetist suspected an neuromuscular blocking agent, the culprit was confirmed by the panel, and in 14%, an alternative culprit was identified. The ratio of suspected/confirmed cases was 1.4 for atracurium, 1.3 for rocuronium, and 1.1 for succinylcholine (Table 5) .
Previous exposure to pholcodine was recorded in only two patients, both of whom had neuromuscular blocking agentinduced anaphylaxis (rocuronium and succinylcholine), but no conclusions can be drawn because of a very limited recording of pholcodine exposure. No episodes were caused by neostigmine. The anaesthetist suspected that sugammadex was the suspected trigger agent in two cases, and one of these 
Chlorhexidine
There were 18 cases of chlorhexidine-induced anaphylaxis, representing 9% of culprits. The Allergen Survey 14 identified 2 298 567 exposures to chlorhexidine by at least one route annually (74% of all cases). Based on NAP6 data, the incidence of anaphylaxis to chlorhexidine is 0.78 per 100 000 exposures, likely an overestimate, as almost all patients are exposed to chlorhexidine during anaesthesia and surgery. Despite reporting chlorhexidine allergy before the event, one patient was exposed, resulting in anaphylaxis. One patient reported a prior reaction during anaesthesia that was not investigated and reacted to chlorhexidine when exposed. One patient experienced a subsequent reaction to chlorhexidine despite confirmation of allergy to chlorhexidine after an investigation of the index NAP6 event. There was one fatal reaction. Eight reactions were Grade 4 and nine were Grade 3. Consistent with published data, most cases were in males (16/ 18) . Ten patients were ASA 2 and eight were ASA 3. Urology (six cases), cardiac (three cases), and orthopaedic (three cases) surgery accounted for the majority of cases.
The anaesthetist suspected chlorhexidine in only five (28%) cases. Reactions to cutaneous chlorhexidine were mostly slower than other agents and of lower grade. There was quicker onset and greater severity in patients with exposure via a coated central venous catheter (CVC) (mostly onset <5 min of exposure and Grade 4 events) than those with only topical surgical site exposure (mostly onset at 1 h and Grade 3 events). Approximately two-thirds of cases presented with hypotension and none presented with bronchospasm ( Supplementary Fig. S2 ).
Patent Blue dye
We identified nine (3.4%) cases of Patent Blue dye-induced anaphylaxis: five were Grade 3 and four were Grade 4. Based on an estimated 61 768 annual exposures, 14 the incidence of anaphylaxis to Patent Blue dye was 14.6 per 100 000 administrations (i.e. higher than succinylcholine). All patients were female: eight were scheduled for breast cancer surgery, and this was abandoned in two cases. Onset was slower than other trigger agents with only two cases <5 min, four presented after >15 min, including two after >60 min. Hypotension was the commonest presentation: all patients became significantly hypotensive, and in three cases, 
Miscellaneous trigger agents
We identified three cases of anaphylaxis to succinylated gelatin solutions and two to blood products. Ondansetron, propofol, aprotinin, protamine, and ibuprofen were responsible for a very small number of cases. The Allergen Survey estimated that 48 203 UK patients are exposed to gelatin-based i.v. fluids during anaesthesia each year, 14 giving an approximate incidence of 6.2 per 100 000 administrations, a rate similar to rocuronium.
Reporting
As reporting is a positive action, it was inferred that this did not take place where the information was not provided. Nine per cent of cases were reported to Medicines and Healthcare products Regulatory Agency (MHRA) by the anaesthetist, 8.3% by the Local Coordinator, 3% by the allergy clinic, and 2.6% by others, including critical care staff. Only three deaths and nine of 31 who survived cardiac arrest (29% combined) were reported to the MHRA. Reporting to the Trust's critical reporting incident system was performed in 70% of cases (including eight of 10 deaths, and 24 (77%) of 31 cardiac-arrest survivors). Of these 187 cases, 160 were reported by an anaesthetist, six by the nursing team, and five by the surgical team.
Discussion
The overall incidence of perioperative anaphylaxis was estimated to be 1 in 10 000 anaesthetics. This may be an underestimate. We excluded 17.5% of cases with a Parts A and B form. If all 541 submissions had included both parts of the form and the same proportion (17.5%) were excluded, the maximum number of cases of anaphylaxis would have been 446, an increase of 67%. This equates to an incidence of 1:7000 cases. As we do not know why, for many cases, some parts of the forms were not submitted, we cannot state whether this higher estimate is reliable.
Previous estimates of incidence of hypersensitivity are similar, but the majority included perioperative hypersensitivity of all grades: despite including only Grades 3e5, our estimated incidence is at least as high. It is possible that the incidence of perioperative anaphylaxis is rising, perhaps as a result of increasing antibiotic sensitisation in the population, and it is notable that antibiotics have overtaken neuromuscular blocking agents as the most frequent trigger agents. Irrespective of absolute incidences, because of our methodology, we believe our results accurately represent the relative incidence with different trigger agents.
Presenting features
Perioperative anaphylaxis has several unusual if not unique elements. First, the vast majority of triggers are administered intravenously, therefore, having the potential for the most rapid and severe reactions. Second, multiple drugs are administered almost concurrently. These routinely alter normal physiology, such that hypotension, arrhythmia, bronchospasm, and even rash may be more commonly attributable to causes other than anaphylaxis. Lastly, the events occur in the immediate presence of a trained 'resuscitationist' who may be able to identify and manage the event more promptly than in many other settings.
Variations in presenting clinical features between different patient groups, with different drugs and with different severities of reactions, are all notable and add to the available literature. It is worth noting that hypotension was universal. Bronchospasm was less common, but was more often seen in the obese and those with pre-existing asthma. Rash was rarely present, sometimes missed (the patient hidden under drapes) and was particularly uncommon in the most severe cases, often only occurring when BP and presumably perfusion had been restored. Bradycardia was relatively common, again in the more severe events, and arrhythmias were rare. Airway complications were almost absent.
Fatalities
Our data suggest that perioperative anaphylaxis was more likely to be fatal in patients who were older, of a higher ASA physical status, and significantly obese. Unlike anaphylaxis in the community, 16 we found no evidence of asthma as a risk factor for fatal perioperative anaphylaxis, but coronary artery disease and administration of beta blockers and or ACE inhibitors were prominent. Patients died despite prolonged attempts at resuscitation, with most aspects of care being rated as good as described in detail in the accompanying paper. 15 
Cardiac arrest and survivors
Most patients who survived cardiac arrest were younger and fitter than those who died. Prescription of ACE inhibitors was again prominent in those who developed cardiac arrest. A considerable majority of cardiac arrests were PEA, and the absence of tachyarrhythmias either as a primary event or secondary to epinephrine (adrenaline) administration is notable.
Profound hypotension
A group of patients, who had profound hypotension, without being designated as 'in cardiac arrest', was identified during review as an apparently high-risk cohort with some poor outcomes. There was discussion regarding the point at which cardiac compressions should be started and, after seeking wide expert advice, we agreed this should be 50 mm Hg, so any patient with a lowest systolic BP <50 mm Hg was designated as requiring cardiopulmonary resuscitation, and therefore, Grade 4, and where cardiac compressions were not started, this was judged to have been an omission. This is a newly identified group and perhaps contentious. Their management and outcomes are discussed in the accompanying paper. 15 
Antibiotics
In contrast to many published series, 3, 17, 18 antibiotics, not neuromuscular blocking agents, were the most common causes of perioperative anaphylaxis. The high frequency of teicoplanin-induced anaphylaxis is noteworthy and likely presents an upward trend. Our findings demonstrate that the administration of teicoplanin is closely related to patientreported penicillin allergy, the most commonly reported drug allergy in the community with up to 10% of the population labelled as allergic. It is likely that the majority are mislabelled and that at least 90% could be de-labelled if an adequate description of the original reaction could be obtained or the patient was investigated in an allergy clinic. 19 More than half of all cases received an antibiotic, almost all of which were administered after the induction of anaesthesia, with signs of anaphylaxis identified in <5 min in most cases and almost all in <10 min. Anaphylaxis-induced hypotension is likely to be exacerbated by general or neuraxial anaesthesia. Therefore, there is a strong argument for antibiotics to be administered several minutes before the induction of anaesthesia. There are several potential benefits: first, lack of known allergy can be confirmed with the patient immediately before administration; second, the severity of physiological derangement caused by anaphylaxis might be less; and third, investigation of anaphylaxis is considerably simplified if fewer drugs have been administered.
It is likely that some of the anaphylactic reactions to antibiotics could have been avoided. This is particularly likely to be the case in patients reported to be allergic to penicillin who were then given teicoplanin, which had a 17-fold higher risk of anaphylaxis than flucloxacillin (or cefuroxime). If it were possible to identify the >90% of patients who report penicillin allergy, but who are not, then avoidance of second-line antibiotics would likely lessen the overall risk of perioperative anaphylaxis significantly. Of note, second-line antibiotics are more expensive and, particularly when used for treatment, are associated with increased duration of treatment, hospital stay, and antibiotic resistance.
20e22 It is currently impractical for all putative penicillin allergy to be investigated in allergy clinics before operation, and the process is significantly complex. However, with the ever-increasing importance of antibiotic stewardship, avoidance of a spurious label of 'penicillin allergic' is an area ripe for research. Thirteen patients with anaphylaxis caused by coamoxiclav and four of those with anaphylaxis to teicoplanin had received an i.v. 'test dose' of between 5% and 30% of the therapeutic dose. It cannot reasonably be expected that a single test dose will eliminate the risk of anaphylaxis. In the allergy clinic, the starting dose for drug challenge (which starts only after negative skin testing) will vary depending on the severity of the index reaction, the dose that is believed to have caused it, the patient's concurrent co-morbidities, whether the challenge is oral or i.v., and the drug itself. With some highrisk drug challenges, this can be as low as 0.1% of the therapeutic dose increasing in 2-to 10-fold increments. NAP6 provides evidence that anaphylaxis occurring after a test dose is no less severe than after a full dose. A third of UK anaesthetists routinely administer a test dose when administering an i.v. antibiotic, 23 despite guidelines from the Association of Anaesthetists of Great Britain and Ireland (AAGBI) advising against their use, 7 and we find no evidence to support the practice.
Neuromuscular blocking agents and reversal agents
In previous studies, neuromuscular blocking agents (NMBAs) were responsible for 40e66% of all cases of perioperative anaphylaxis. 18, 24 Sensitisation to NMBAs can occur during anaesthesia, but the majority of patients do not give a history of previous exposure, 25 and environmental exposure to the quaternary ammonium epitope has been implicated in generating NMBA allergy. 26 In addition, pholcodine-containing cough medicines might cause sensitisation to NMBAs 27 : NMBA sensitisation has declined in Norway since the withdrawal of pholcodine cough medicine. 28 Non-allergic anaphylaxis can occur with atracurium and mivacurium. Recent evidence implicates specific receptors on the surface of mast cells. 29 Variation in receptor expression might explain why these drugs cause dramatic noneIgEmediated mediator release in some individuals.
No previous study has undertaken parallel investigation of incidence and NMBA exposure during a 1 yr period. In a study of concomitant exposure and anaphylaxis rates over a 6 yr period, the pattern of perioperative anaphylaxis might not have been constant. 30 Studies relying on sales of drug ampoules to estimate the number of patient exposures may not estimate the denominator accurately. Ampoule sales of succinylcholine likely overestimate usage as a result of waste. To avoid these pitfalls, NAP6 surveyed the number of patients receiving NMBAs during the same year as the case-reporting phase.
NMBAs accounted for about one-third fewer cases of anaphylaxis than antibiotics, but carry at least as high a risk as antibiotics per administration, with the exception of teicoplanin. The lower occurrence rate of NMBA-induced anaphylaxis observed is caused by z2.5 million administrations of antibiotics to surgical patients per year compared with z1.2 million administrations of NMBAs. Succinylcholine is well known to carry a greater risk of anaphylaxis than other NMBAs, which our data confirm. The risk of succinylcholine-induced anaphylaxis was about twice that of all other NMBAs.
It has been suggested previously that rocuronium is associated with a relatively higher risk of anaphylaxis than vecuronium. 31 In that study, the incidence of succinylcholine anaphylaxis could not be accurately estimated through lack of denominator data. Vecuronium is used only rarely in the UK.
14 Although our data cannot be definitive regarding the relative incidence of atracurium-and rocuronium-induced anaphylaxis, we identified no major difference in their observed incidences, and our data should not be interpreted as indicating that rocuronium is a more frequent culprit than atracurium. The difficulties inherent in interpreting the reported incidences of uncommon anaphylactic events have been described. 32 In particular, marginal under-reporting has a disproportionately large effect on calculated incidence when the event being recorded occurs only very rarely. Anaesthetists tended to overestimate the number of cases caused by NMBAs, perhaps as a result of their well-known allergenic potential.
We are unable to comment on the possible influence of pholcodine consumption on the incidence of NMBA anaphylaxis. This information was not recorded in two-thirds of reports, and only 18% of allergy clinics routinely seek this information. 33 A single case of sugammadex-induced anaphylaxis was reported. Onset was delayed, and anaphylaxis should be considered among other differential diagnoses if a patient deteriorates in the recovery room. Sugammadex used as treatment for anaphylaxis is discussed in the accompanying paper. 15 
Chlorhexidine
Perioperative chlorhexidine exposure can occur via topical skin disinfection, chlorhexidine-coated CVCs, and use of chlorhexidine-containing lubricating gels. 9 It might not be NAP6: epidemiology and clinical features -167 immediately obvious that these products contain chlorhexidine, which has been called 'the hidden allergen'. 34 There are geographical differences in the incidence of chlorhexidine-induced perioperative anaphylaxis: 7.7% in the UK 35 and 9.3% in Denmark 36 ; rare in France. 37 The cause for the variation is not clear, but might be related to underrecognition and differences in practice (e.g. more use of povidone iodine and lower use of chlorhexidine-coated catheters).
As exposure to chlorhexidine is highly likely in any surgical setting, several centres routinely test all patients referred with perioperative anaphylaxis for chlorhexidine allergy. In countries adopting this practice, chlorhexidine allergy is generally commonly identified. 35, 36 Sensitisation to chlorhexidine can occur in healthcare settings or the community, as chlorhexidine-containing products are found in both environments. 38 Chlorhexidine is not yet considered among the 'mainstream' causes of perioperative anaphylaxis, despite evidence to the contrary. This is reflected by lost opportunities during perioperative history taking and the low suspicion rate we observed. Previously, up to 80% of patients diagnosed with chlorhexidine allergy reported possible chlorhexidine allergy that could have been identified before their adverse reaction. 39, 40 Despite an alert relating to chlorhexidine-containing medical products and devices being issued nationally by MHRA in 2012, 41 it appears that many clinical staff are unaware of which products contain this antiseptic and the risks of anaphylaxis. It is unsurprising that reactions are more rapid and severe when a CVC is the source of the chlorhexidine and the allergen is delivered directly to the circulation. Removing the CVC is central to treating the reaction under these circumstances.
Patent Blue dye
Patent Blue dye is found as a food dye (E131), approved for use in the UK, but not in the USA, Australasia, Japan, and several other countries. It structurally resembles other triarylmethane dyes widely used in manufacturing. During surgery, it is injected into the tissues and taken up by the lymphatic system enabling sentinel lymph nodes to be seen directly. Sensitisation is likely caused by environmental exposure to the dye or a cross-reacting epitope. The reported estimated incidence of allergic reactions, which are commonly mild, varies between 150 and 1000 per 100 000 administrations. 11,42e44 Reactions are frequently delayed 30e60 min, possibly because of the slow absorption from subcutaneous tissues and lymphatics. 43 As Patent Blue dye interferes with pulse oximetry (causing spuriously low readings), there is a potential delay in the recognition of onset of anaphylaxis. While two studies examining this effect reported mean reductions in digital oxygen saturation (SpO 2 ) of <2%, 11, 45 in some individuals, considerably greater falls can be observed. 46, 47 In NAP6, reactions to Patent Blue dye were relatively common, were severe, and required significant resuscitation. Cutaneous signs were absent in a third of patients, and absence of rash should not dominate the differential diagnosis. As hypoxaemia is common after perioperative anaphylaxis, any fall in oxygen saturation should be assumed to be real until a blood gas analysis has ruled this out.
Miscellaneous agents
The very small number of cases of reactions to blood products (and none to red blood cells) is notable. The Activity Survey estimated approximately 84 000 perioperative administrations of blood products. The relative infrequency of these is perhaps attributable to the success of the serious hazards of transfusion haemovigilance scheme (https://www.shotuk.org/). 48 Ondansetron is administered during an estimated 77% of general anaesthetics and 66% of all cases involving anaesthetist-delivered care.
14 Just two cases report of ondansetron-induced anaphylaxis indicates its extreme rarity. However, these reactions can be severe: two cases of fatal anaphylaxis attributed to ondansetron have been reported. 49 We observed a single case of propofol allergy. Propofol is an extremely uncommon cause of anaphylaxis. Our survey data indicate that well over 2 million patients in the UK are exposed to this induction agent perioperatively each year.
14 Twentyfour IgE-mediated cases were reported in a French 8 yr study 3 and two cases were recorded in a UK 7 yr single-clinic study. 5 Propofol-induced anaphylaxis might occur in some patients via a noneIgE-mediated mechanism. 50 Skin testing is negative in this situation, and controlled provocation testing with i.v. propofol would be necessary to confirm the diagnosis, a procedure that is not generally available. The same publication dispelled the notion that propofol is contra-indicated in adults who are allergic to egg, soya, or peanut, but some uncertainty still exists in children who have experienced anaphylaxis to egg. 51 A diagnosis of hypersensitivity to propofol has serious implications for the patient, given the ubiquity of this induction agent, and therefore, merits a full investigation. We recorded one case of anaphylaxis to protamine in a patient with diabetes mellitus. It has been suggested that patients who have been exposed to neutral protamine Hagedorn insulin, which contains protamine, are more likely to experience protamine-induced anaphylaxis. 52 Fish allergy has been implicated as a risk factor for protamine anaphylaxis, as protamine is traditionally extracted from the sperm of fish. This risk may decrease as the drug becomes increasingly synthesised by recombinant biotechnology. Anaphylaxis caused by non-steroidal anti-inflammatory drugs (NSAIDs) has been comprehensively reviewed. 53 There is a wide spectrum of severity and pathogenesis. Reactions are commonly non-immunologically mediated and there can be cross-reactivity to drugs sharing cyclooxygenase-1 enzyme inhibition. An 8 yr national study in France identified only three immunologically mediated perioperative hypersensitivity reactions to NSAIDs. 3 
Reporting
Reporting of cases of anaphylaxis to the hospital and the MHRA was disappointingly low. All NAP6 cases were at least Grade 3, representing a life-threatening incident, yet almost a third were not reported to the hospital's critical incident reporting system, reducing the likelihood of lessons being learned where applicable. Few cases were reported to the MHRA despite AAGBI guidance to do so, irrespective of severity of the outcome. Local Coordinators were responsible for many of the reports to the MHRA, so in normal circumstances, such reporting might be even lower. Our data imply that pharmacovigilance is not being supported adequately, and further mean that data reported back to anaesthetists and allergy clinics by the MHRA are likely to be unreliable. Factors contributing to poor reporting-rates have been discussed. 54 
Conclusions
We believe this is the largest study of life-threatening perioperative anaphylaxis that incorporates contemporaneous real-life data on exposure to potential allergens, permitting the calculation of accurate relative-incidence rates. Antibiotic allergy is an increasing problem, particularly to teicoplanin; optimising the preoperative allergy history could reduce the number of these perioperative anaphylactic reactions. Our data should dispel any notion that test doses prevent or ameliorate anaphylaxis. An awake patient is able to report early symptoms of evolving anaphylaxis, and our data support administering antibiotics before the induction of anaesthesia if practical. Early recognition is key to a successful treatment, and our results show that the initial presentation can be varied, likely to be bronchospasm if succinylcholine is the trigger agent, and can be delayed, particularly with Patent Blue dye and some exposures to chlorhexidine, the 'hidden allergen'. Patient factors, such as ASA physical status, obesity, and use of beta blockers and ACE inhibitors, influence the clinical features of perioperative anaphylaxis, a dimension previously under-reported. Risk of anaphylaxis should not be a determining factor in the choice between rocuronium and atracurium. Anaesthetists should report cases through the MHRA Yellow Card Scheme so that pharmacovigilance can be better supported in the future. This is the first of two companion papers describing the main findings of NAP6; in the second, 15 we describe clinical management and outcomes, and make recommendations for organisational and individual practice.
